Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recovery after impacted mandibular third molar extraction with serratiopeptidase or escin
ISRCTN15432618Phase 3Completed
- Sponsor
- University of Science and Technology, Yemen
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of serrapeptase and escin in postoperative pain, edema and trismus (3 arms), sponsored by University of Science and Technology, Yemen. Primary endpoints: Facial edema, Trismus and 1 more. Started Jul 2024; status: completed.
02
Drugs
serrapeptaseescin
03
Conditions
postoperative painedematrismus
Beyond the preview
Go deeper on ISRCTN15432618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15432618.